

## Molecular cloning and functional expression of a novel *Helicobacter pylori* $\alpha$ -1,4 fucosyltransferase

Said Rabbani<sup>2</sup>, Viktoria Miksa<sup>2</sup>, Beat Wipf<sup>3</sup>,  
and Beat Ernst<sup>1,2</sup>

<sup>2</sup>Institute of Molecular Pharmacy, Pharmazentrum, University of Basel,  
Klingelbergstrasse 50, CH-4056 Basel, Switzerland; and

<sup>3</sup>Hoffmann-La Roche, CH-4002 Basel, Switzerland

Received on December 17, 2004; revised on June 23, 2005; accepted on  
June 23, 2005

*Helicobacter pylori* is an important human pathogen which causes both gastric and duodenal ulcers and is associated with gastric cancer and lymphoma. This microorganism synthesizes fucosylated oligosaccharides, predominantly the Gal $\beta$ -1,4GlcNAc (Type II) blood group antigens Lewis X and Y, whereas a small population also expresses the Gal $\beta$ -1,3GlcNAc (Type I) blood group antigens Lewis A and B. These carbohydrate structures are known to mimic host cell antigens and permit the bacteria to escape from the host immune response. Here, we report the cloning and characterization of a novel *H. pylori*  $\alpha$ -1,4 fucosyltransferase (FucT). In contrast to the family members characterized to date, this enzyme shows exclusively Type I acceptor substrate specificity. The enzyme consisting of 432 amino acids (MW 50,502 Da) was cloned using a polymerase chain reaction (PCR)-based approach. It exhibits a high degree of identity (75–87%) and similar structural features, for example, in the heptamer repeat pattern, with other *H. pylori* FucTs. The kinetic characterization revealed a very efficient transferase ( $k_{\text{cat}}/K_m = 229 \text{ mM}^{-1}\text{s}^{-1}$ ) for the Type I acceptor substrate (Gal)-1,3GlcNAc-Lem (1). Additionally, the enzyme possesses a broad tolerance toward nonnatural Type I acceptor substrate analogs and therefore represents a valuable tool for the chemoenzymatic synthesis of Lewis A, sialyl Lewis A as well as mimetics thereof.

**Key words:** enzymatic synthesis/*Helicobacter pylori*/sialyl Lewis<sup>a/x</sup> and mimetics thereof/ $\alpha$ -1,4 fucosyltransferase

### Introduction

Fucosyltransferases (FucTs) are the enzymes responsible for the last step in the synthesis of Lewis antigens. They catalyze the transfer of fucose (Fuc) from guanidine 5'-diphospho- $\beta$ -L-fucose (GDP-fucose) to oligosaccharide acceptors to form  $\alpha$ 1,2 (Larsen *et al.*, 1990),  $\alpha$ 1,3 (Weston *et al.*, 1992), and  $\alpha$ 1,4 linkages (Kukowska-Latallo *et al.*, 1990).

Although the chemical synthesis of carbohydrates is well developed (for reviews, see Ernst *et al.*, 2000a), the preparation of a particular oligosaccharide still remains a costly and cumbersome challenge. A complementary approach to the chemical synthesis of physiologically important oligosaccharides is the combined use of chemical and enzymatic methods. It has also been shown that glycosyltransferases can be successfully employed for the synthesis of a wide range of nonnatural oligosaccharides as well (Palcic and Hindsgaul, 1991; Baisch *et al.*, 1996a,b,c; Gijsen *et al.*, 1996; Ernst and Oehrlein, 1999; Ernst *et al.*, 2000b; Seto *et al.*, 2000; Blixt *et al.*, 2002; Bintein *et al.*, 2003). For their heterologous production mammalian (Larsen *et al.*, 1990; Kitagawa and Paulson, 1994) and baculovirus expression systems (Morais *et al.*, 2001; Kim *et al.*, 2003) as well as yeast (Malissard *et al.*, 2000) have been used.

Recently, several reports demonstrated the ability of human pathogenic bacteria such as *Helicobacter pylori* (Chan *et al.*, 1995; Martin *et al.*, 1997; Monteiro *et al.*, 1998; Wang *et al.*, 2000), *Campylobacter jejuni* (Gilbert *et al.*, 2000), *Neisseria gonorrhoeae*, and *Neisseria meningitidis* (Gilbert *et al.*, 1996) to synthesize Lewis A and B as well as Lewis X and Y blood group antigens. As constituents of membrane lipopolysaccharides, these oligosaccharides mimic the host cell antigens and permit the bacterium to escape from the immune response (Appelmek *et al.*, 1996; Wirth *et al.*, 1996; Gilbert *et al.*, 2000). The sequenced genome of two strains of the gastric pathogenic bacterium *H. pylori* revealed many putative FucT sequences (Tomb *et al.*, 1997; Alm *et al.*, 1999). As a consequence, the cloning and expression of *H. pylori*  $\alpha$ -1,2 (Wang *et al.*, 1999),  $\alpha$ -1,3 (Ge *et al.*, 1997; Martin *et al.*, 1997) and  $\alpha$ -1,3/4 FucTs (Rasko *et al.*, 2000) has been reported.

Our interest in glycosyltransferases for the preparative chemoenzymatic synthesis of carbohydrates prompted us to search for cost effective sources. In this study, we report the cloning, functional expression, and characterization of a novel *H. pylori*  $\alpha$ -1,4 FucT in *Escherichia coli* and its preliminary use for the chemoenzymatic synthesis of Lewis A, Gal $\beta$ -1,3(Fuc $\alpha$ -1,4)GlcNAc (Le<sup>a</sup>), sialyl Lewis A, NeuNAc $\alpha$ -2,3Gal $\beta$ -1,3(Fuc $\alpha$ -1,4)GlcNAc (sLe<sup>a</sup>), and mimetics thereof.

### Results

#### Cloning of a *H. pylori* fucosyltransferase

In order to clone a gene encoding an  $\alpha$ -1,3 or  $\alpha$ -1,3/4 FucT in *H. pylori* strain DMS 6709, primers derived from the highly homologous *H. pylori* FucT sequences available in

<sup>1</sup>To whom correspondence should be addressed; e-mail:  
beat.ernst@unibas.ch

NCBI Genbank (AF194963, AAD06573 and AAD06169) were designed and used to amplify a PCR product of 1375 bp. The fragment was double-digested by EcoRI/BamHI and cloned into the expression vector pEZZ18. This vector offers the advantage of generating a recombinant protein containing two synthetic IgG-binding domains (ZZ) of *Staphylococcus aureus* protein A and an export signal for protein secretion in the culture medium. After transformation in *E. coli*, five positive clones were selected according to PCR and restriction enzyme control. The sequence of their first 400–500 bp from the N-terminus showed 100% identity at the amino acid level. Protein expression was carried out with three clones resulting in a secreted fusion ZZ-FucT polypeptide with a calculated molecular mass of 64,502 Da. FucT without ZZ-fusion domain encodes a 436-amino acid polypeptide with a predicted molecular mass of 50,502 Da. The full nucleotide sequence for one clone was confirmed by the double-stranded sequencing strategy and registered at the GenBank™/EBI Data Bank (AY450598).


#### Features of the novel *H. pylori* fucosyltransferase sequence

The nucleotide and the deduced amino acid sequence of the cloned FucT are shown in Figure 1A. The Kyte–Doolittle plot analysis shows a very hydrophilic protein without any transmembrane segments (Figure 1B). A sequence blast of our new FucT against the *H. pylori* genomes of J99 and 26695 strains demonstrates a high degree of similarity to two FucTs in strain J99 (NP223719.1 and NP223314.1) and two  $\alpha$ -1,3 FucTs in strain 26695 (NP207177.1 and NP207445.1). The alignment of the amino acid sequence revealed a high degree of similarity to other *H. pylori* FucTs, for example 87% identity to the  $\alpha$ -1,3 FucT (Martin *et al.*, 1997) and 75% identity to the  $\alpha$ -1,3/4 FucT (Rasko *et al.*, 2000). This is in agreement with human FucTs sharing a high level of amino acid sequence similarity even when they exhibit distinct acceptor substrate specificities (Kukowska-Latallo *et al.*, 1990; Weston *et al.*, 1992; Xu *et al.*, 1996). In analogy to other *H. pylori* FucT sequences, the new FucT also contains repetitive sequences of the heptapeptide DDLRINY close to the C-terminus (Figure 1A). However, there are only four instead of seven, eight or ten repeats observed in *H. pylori*  $\alpha$ -1,3 FucT (strain NCTC11637, Chan *et al.*, 1995), *H. pylori*  $\alpha$ -1,3/4 FucT (strain UA948, Rasko *et al.*, 2000), and *H. pylori*  $\alpha$ -1,3 FucT (strain NCTC11639, Ge *et al.*, 1997), respectively. The intervals between the leucines show a high regularity similar to the eukaryotic leucine zipper motif, which is believed to be involved in protein–protein and protein–DNA interactions (Landschulz *et al.*, 1988). The peptide motif YxFxLxFENSxxxxYxTEK found in *H. pylori*  $\alpha$ -1,3/4 FucT (Rasko *et al.*, 2000) as well as in the bovine FucT III (Oulmouden *et al.*, 1997), the panther FucT III (Costache *et al.*, 1997), human  $\alpha$ -1,3/4 FucT (FucT III, Kukowska-Latallo *et al.*, 1990), and human  $\alpha$ -1,3 FucT (FucT V, Weston *et al.*, 1992) is also conserved in the novel *H. pylori* FucT sequence (Figure 1A and C). Finally, in the reported *H. pylori* FucT a peptide sequence (343–352 : CDAH-NYSALH) similar to *H. pylori*  $\alpha$ -1,3/4 FucT (345–354: CNDAHYSALH) is present (Ma *et al.*, 2003) (Figure 1A). It seems to be related to the acceptor specificity.

#### (A)

```
atgttcacgaccttactagacgcttatatagacagcaccggttagatgaaaccgattat
M F Q P L L D A Y I D S T R L D E T D Y
aagccccccctaaaaatcgctgtggcgaaatgggtggggagggcgttgaagaatttataaaag
K P P L K K I A V A N W W G G V E E F K K
agcactcttttatttcatcttaagccaacgctacacaatcactttacaccgaaaccctgat
S T L Y F I L S Q R Y T I T L H R N P D
aaacctgcgacatcggtttttgttaacctcttggatcggttagaataatcttatcttat
K P A D I V F G N P L G S A R K I L S Y
caaaacgcaaaaagagtggttttacacgggtgaaatgaagtccttaacttcaacctcttt
Q N A K R V F Y T G E N E V P N F N L F
gattacgccataggcttgatgaattggattttaatgatcggttatttgagaatgccttg
D Y A I G F D E L D F N D R Y L R M P L
tattacgcccactctgactatgaagctgagctgttgaatgacaccacttcaccttacaag
Y Y A H L H Y E A E L V N D T T S P Y K
atataagcaaacgctttatgcttttaaaaaacaccttccatcatttttaagaaaaaccac
I K D N S L Y A L K K P S H F K E N H
cctaatttgtgcgtagtgaaatgaagtgatcctttgaaaagaggggttgcgagt
P N L C A V V N N E S D P L K R G F A S
ttgttcgagcgaacacctaacgctcctaaaggaacgctttctatgacgctttaaattct
F V A S N P N A P K R N A F Y D A L N S
attgacgagcttgggggagggcggtgaaacacactctgggttataatgtcaaaac
I E P V T G G G S V K N T L G Y N V K N
aaaaacgagtttttaagcaatacaagttcaacctgtgttttgaaaactcgcaagggtat
K N E F L S Q Y K F N L C F E N S Q G Y
ggctataactgaaaaatccttgacgcttatttcagccacaccattccatttatttg
G Y V T E K I L D A Y F S H T I P I Y W
gggagctccagcgtggcgaaagattttaacctaaagattttgtgaatgtgcatgatttc
G S P S V A K D F N P K S F V N V H D F
aacaactttgtgaagcgattgatcatgtgcgatacctacacgacccaacacgcttat
N N F D E A I D H V R Y L H T H P N A Y
ttgacatgctttatgaaacacctttgaacaccttgatgggaaagcttactttaccaa
L D M L Y E N P L N T L D G K A Y F Y Q
aattgagtttttaaaaaatcctagatttttttaaaacgattttgaaacgatacagatt
N L S F K K I L D F F K T I L E N D T I
tatcatgctgacccataattattctgctcttcatcggttgaatgagccggttagtg
Y H C D A H N Y S A L H R D L N E P L V
tccatttgatgatttgagaatcaattatgatgatttgagaatcaattatgatgatttga
S I D D L R I N Y D D L R I N Y D D L R
atcaattatgatgatttgagaatcaattatgagcgccttttgcaaaacgcttcgcttta
I N Y D D L R I N Y E R L L Q N A S P L
ttggaattatcccaaaacacctcttttaaaatctatcgcaaaacccatacaaaatcccta
L E L S Q N T S F K I Y R K A Y Q K S L
cccttgctgcgcccataaggagatgggttataaaataagtttgtaaaacaaacccatca
P L L R A I R R W V K K - V C K T N P S
aacccttgcgctatcatcgacagcgtacttt
N P L R Y H R R R Y F
```

#### (B)



**Fig. 1.** (A) Nucleotide sequence and deduced amino acids sequence of the novel *Helicobacter pylori*  $\alpha$ -1,4 fucosyltransferase (FucT). The heptamer-repeat motifs are underlined and in boldface type. Residues denoted by boldface type represent the conserved  $\alpha$ -1,3 (Martin *et al.*, 1997) and  $\alpha$ -1,3/4 FucT (Rasko *et al.*, 2000) motifs. Residues denoted in italic and boldface type seem to govern the Gal $\beta$ -1,3GlcNAc (Type I) acceptor substrate specificity (Ma *et al.*, 2003). (B) Kyte–Doolittle hydropathy profile of the novel *H. pylori*  $\alpha$ -1,4 FucT based on the DNA sequence. The enzyme shows a very hydrophilic profile without any transmembrane segments. (C) Amino acid sequence alignment of the bovine (Q1126), panther (O19058), human FucT III (P21217), human FucT V (Q11128), and *H. pylori*  $\alpha$ -1,3/4 FucT (Q9L8S4) with the novel *H. pylori*  $\alpha$ -1,4 FucT. The conserved  $\alpha$ -1,3/4 FucTs peptide motif is indicated in boldface type.

(C)

Bovine FucT III	QLSQYKFYLA	FENSLHPDYI	TEKLWKNALQ	AWAVPVVLGP	SRVNYEQFLP
Panther FucT III	TLSRYKFYLA	FENSLHPDYI	TEKLWRNALE	AWAVPVVLGP	SRSNYERFLP
Human FucT III	TLSRYKFYLA	FENSLHPDYI	TEKLWRNALE	AWAVPVVLGP	SRSNYERFLP
Human FucT V	TLSRYKFYLA	FENSLHPDYI	TEKLWRNALE	AWAVPVVLGP	SRSNYERFLP
<i>H. pylori</i> $\alpha$ -1,3/4 FucT	FLSQYKFNLCL	FENSQGYGYV	TEKIL.DAYF	SHTIPIYWGS	PSVAKDFNPK
<i>H. pylori</i> $\alpha$ -1,4 FucT	FLSQYKFNLCL	FENSQGYGYV	TEKIL.DAYF	SHTIPIYWGS	PSVAKDFNPK
Consensus	Y.F.L.	FENS....Y.	TEK....A..	....P....G	

Fig. 1. continued

#### Expression and affinity purification of the recombinant soluble *H. pylori* fucosyltransferase

The vector containing the recombinant enzyme was transformed into the *E. coli* strains Top10, DH $\alpha$ 5, and AD494. The AD494 strain cultivated in TB medium showed the highest level of enzyme expression (5 mg/L and 5U/mg) and therefore was used for further enzyme production. *E. coli* AD494 strain is a thioredoxin reductase mutant that enables disulfide bond formation and thus provides the potential to produce properly folded proteins (Derman *et al.*, 1993). The soluble enzyme secreted in the culture medium was recovered in a one step procedure by affinity chromatography using a GDP-hexanolamine column leading to much higher yields of active FucT than affinity purification with IgG sepharose (data not shown). The recombinant enzyme was stable for several months at  $-70^{\circ}\text{C}$  in cacodylate buffer containing 10% glycerol.

#### Sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis


To verify the degree of purification, the novel FucT was analyzed by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) followed by silver staining showing a single band at the expected molecular mass of approximately 64.50 kDa (Figure 2). In addition, Figure 2 also shows the difference in the level of FucT expression in

*E. coli* AD494 (clone 1) as compared to other strains (DH $\alpha$ 5 and Top10).

#### Acceptor specificity of the recombinant soluble *H. pylori* FucT

To determine the specificity of the novel FucT, Gal $\beta$ -1,3GlcNAc (Type I) and Gal $\beta$ -1,4GlcNAc (Type II) disaccharides as well as their  $\alpha$ -2,3 sialylated forms were used as acceptors and GDP-fucose as donor (Figure 3). All acceptor substrates contain the lipophilic Lemieux substituent (Lem :  $\text{O}(\text{CH}_2)_8\text{COOMe}$ ) at the reducing end to facilitate the purification of the fucosylated products on Sep–Pak–C<sub>18</sub> cartridges (Hindsgaul *et al.*, 1991). The kinetic parameters  $K_m$  and  $k_{\text{cat}}$  obtained are summarized in Table I. Under standard conditions, the novel transferase showed excellent activity with the Type I acceptor substrates **1** and **2**, whereas the Type II acceptor substrates **3** and **4** were only moderately fucosylated even at acceptor substrate concentrations of 2 mM. Thus, the novel bacterial enzyme showed the properties of an  $\alpha$ -1,4 FucT, although the primers used for the sequence generation were derived from  $\alpha$ -1,3 and  $\alpha$ -1,3/4 FucT sequences. This is, however, not astonishing, because high homologies of *H. pylori* FucT sequences are known for the human enzymes. Similar to the human  $\alpha$ -1,3/4 FucT (Kukowska-Latallo *et al.*, 1990), *H. pylori*  $\alpha$ -1,4 FucT accepted 3'-sialyl-lacto-N-biose (**2**) slightly better than lacto-N-biose (**1**). The affinity of the enzyme for the GDP-fucose was very high ( $K_m = 5.73 \mu\text{M}$ ). In general, depending on the strains (UA 861, UA 802, and UA 1182 [Chan *et al.*, 1995] and NCTC 11637 [Martin *et al.*, 1997]), the affinity of bacterial enzymes for GDP-fucose varies from 17 to 140  $\mu\text{M}$  (Chan *et al.*, 1995; Ma *et al.*, 2003).

To study the applicability of the novel  $\alpha$ -1,4 FucT to the preparative enzymatic syntheses of sLe<sup>a</sup> mimetics, modified Type I oligosaccharides containing replacements of the GlcNAc and/or *N*-acetylneuraminic acid (NeuNAc) moiety by noncarbohydrate structures were evaluated. The enzymatic activity was quantified as the amount of radioactivity transferred from GDP-L-[<sup>14</sup>C]Fuc to the corresponding acceptor (in % relative to **1**, Table II). The pseudotrisaccharide **5**, in which GlcNAc is substituted by (*R,R*)-cyclohexan-1,2-diol and NeuNAc by (*R*)-cyclohexyllactic acid showed only minimal acceptor properties (5.1%). The (*S*)-lactic acid derivative **6**, however, proved to be an excellent acceptor substrate (100%). The activity was practically abolished when compound **8** [GlcNAc moiety replaced by (*R,R*)-butan-2,3-diol and NeuNAc by (*S*)-3-phenyllactic acid] was used as acceptor substrate. Finally, reduced activity



**Fig. 2.** Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) analysis of affinity purified *H. pylori*  $\alpha$ -1,4 fucosyltransferase. The enzyme was expressed in AD494, DH $\alpha$ 5, and Top10 *Escherichia coli* cells. Single colonies from each clone (1, 2, 3, and 4) were grown overnight at  $37^{\circ}\text{C}$  and by vigorous shaking (300 rpm) in Terrific Broth medium (TB). The protein purification was performed as described in *Materials and methods*. Equal volumes (10  $\mu\text{L}$ ) from the eluted fractions were separated on 10% SDS–PAGE followed by silver staining. The molecular weight marker (MWM) is indicated on the left.




Fig. 3. Structures of natural (1 and 2) and nonnatural substrates (3–9).

**Table I.** Acceptor substrate specificity of the novel *Helicobacter pylori*  $\alpha$ -1,4 fucosyltransferase: relative enzyme activity (100% correspond to the transfer of 3.76  $\mu$ mol fucose/mg protein/min)

Acceptors	$K_m$ ( $\mu$ M)	$k_{cat}$ (s <sup>-1</sup> )	$k_{cat}/K_m$ (mM <sup>-1</sup> s <sup>-1</sup> )
Gal $\beta$ -1,3GlcNAc-R (1)	114	26.12	229
Sia $\alpha$ -2,3Gal $\beta$ -1,3GlcNAc-R (2)	111	34.33	310
Gal $\beta$ -1,4GlcNAc-R (3)	313	0.067	0.21
Sia $\alpha$ -2,3Gal $\beta$ -1,4GlcNAc-R (4)	432	0.114	0.26
GDP-fucose	5.73	3.947	689

The assay was conducted as described in *Materials and methods*.

was also observed with the acceptor substrates 7 (8.6%) and 9 (2.8%).

#### *N*-ethylmaleimide inhibition assays and thermal stability


FucTs have been discriminated according to their sensitivity to the sulfhydryl-binding reagent *N*-ethylmaleimide, NEM (Chou *et al.*, 1977; Campbell and Stanley, 1984). The human Lewis (FucT III) and the plasma-type (FucT VI) enzymes are inhibited by NEM, whereas others such as the myeloid-type enzyme (FucT IV) are insensitive to NEM

**Table II.** Enzyme activity of the novel *Helicobacter pylori*  $\alpha$ -1,4 fucosyltransferase with Gal $\beta$ -1,3GlcNAc (Type I) and Gal $\beta$ -1,4GlcNAc (Type II) acceptor

Acceptors	Relative activity (%)
1	100
2	133
3	0.3
4	2.7
5	5.1
6	100
7	8.6
8	0.9
9	2.8

The fucosyltransferase assay was run in duplicates using Type I or Type II acceptors and 0.150 mM 5'-diphospho- $\beta$ -L-fucose (GDP-fucose). For the determination of the  $K_m$  for GDP-fucose, 2 mM of Type I acceptor substrate 1 was used. The reactions were quantified as described in *Materials and methods*.

treatment (Holmes *et al.*, 1995). The sensitivity of the novel bacterial  $\alpha$ -1,4 FucT to NEM was very high, as 90% of the enzyme activity was abolished in the presence of 10 mM NEM (Figure 4). In contrast, it has been shown that



**Fig. 4.** *N*-ethylmaleimide (NEM) inhibition of the novel *Helicobacter pylori*  $\alpha$ -1,4 fucosyltransferase. NEM was added to the ice-cooled reaction 30 min before incubation with Gal $\beta$ -1,3GlcNAc $\beta$ Lem (1) to give final concentrations of 0.5–10 mM. The enzymatic reaction was quantified as described in *Materials and methods*.

*H. pylori*  $\alpha$ -1,3 FucT is only minimally inhibited by NEM (Martin *et al.*, 1997).

As next, the applicability of the novel FucT at elevated temperature was tested. The recombinant  $\alpha$ -1,4 FucT shows maximal activity between 37 and 42°C, below (25°C, 70%) and above (50°C, 60%) the catalytic activity was slightly reduced. This is in contrast to human FucT VII ( $\alpha$ -1,4 FucT) expressed in *Sf9* insect cells (Shinkai *et al.*, 1997), which shows a more pronounced deactivation at elevated temperatures (50°C, 35%).

## Discussion

Recently, several putative FucT sequences have been identified in the genome of *H. pylori* (Tomb *et al.*, 1997; Alm *et al.*, 1999). Consequently, considerable attention has been devoted to this bacterium to understand the molecular mechanism of pathogenicity but also to use it as a cost effective source of glycosyltransferases. *Helicobacter pylori* strains express on their surface predominantly lipopolysaccharides containing Type II Lewis antigens (Wirth *et al.*, 1996; Simoons-Smit *et al.*, 1996). Type I Lewis antigens, however, are found only in a limited number of strains (Wirth *et al.*, 1996; Monteiro *et al.*, 1998).

In this study, we report the molecular cloning, functional expression and characterization of a novel *H. pylori*  $\alpha$ -1,4 FucT. Analysis of the predicted protein sequence revealed a high degree of identity to other *H. pylori*, for example,  $\alpha$ -1,3 (Martin *et al.*, 1997; Ge *et al.*, 1997) and  $\alpha$ -1,3/4 FucTs (Rasko *et al.*, 2000). Within the FucT family the high level of sequence homology does not correlate with their substrate specificities (Kukowska-Latallo *et al.*, 1990; Weston *et al.*, 1992). Similar to other *H. pylori* FucT sequences, there is a direct repeat of heptamers close to the C-terminus. However, the number of these repeats is limited to four instead of seven, eight or ten found in other

*H. pylori* FucTs (Ge *et al.*, 1997; Martin *et al.*, 1997; Rasko *et al.*, 2000). The influence of the number of heptameric repeats on the substrate specificity has not been investigated yet. However, the deletion of the ten repeat motifs in *H. pylori* strain NCTC11639 (Ge *et al.*, 1997) generates an inactive transferase, suggesting a role of these motifs in the enzyme function.

Recently, Ma *et al.* (2003) reported the construction of enzyme chimeras by subdomain swapping between  $\alpha$ -1,3 and  $\alpha$ -1,3/4 *H. pylori* FucTs. The result indicates that Type I acceptor specificity seems to be governed by ten amino acids (CNDAHYSAH) corresponding to residues 345–354 in  $\alpha$ -1,3/4 FucT. In the reported *H. pylori*  $\alpha$ -1,4 FucT a similar peptide sequence (343–352) is present (Figure 1A).

The expression of the novel *H. pylori* FucT in *E. coli* AD494 cells yields an enzyme, which fucosylates Gal $\beta$ -1,3GlcNAc $\beta$ -Lem (1) and its  $\alpha$ -2,3 sialylated form 2 with high efficiency (Table I). However, even at acceptor substrate concentrations up to 2 mM, the activity with the *N*-acetylglucosamine (LacNAc) derivatives 3 and 4 was not significant (0.3–2.7%). In contrast to the activity of the *H. pylori*  $\alpha$ -1,3/4 FucT, which is 5 to 20-fold higher with LacNAc compared to the Type I acceptor substrate lacto-N-biose (Rasko *et al.*, 2000), the novel *H. pylori* FucT shows an almost exclusive acceptance for Type I substrates. In preliminary experiments for the preparative chemoenzymatic synthesis of sLe<sup>ax</sup> mimetics as potential E-selectin antagonists, the novel *H. pylori* FucT showed a remarkable tolerance for a variety of nonnatural acceptor substrates (Figure 3, Table II). Although some of the activities were relatively weak, they are still sufficient for a preparative enzymatic approach. Furthermore, these results suggest that NeuNAc can be substituted by analogs with an appropriate stereochemistry, for example [S]-lactic acid derivatives. In addition, these replacements are also tolerated in combination with GlcNAc mimetics such as (*R,R*)-butan-2,3-diol or (*R,R*)-cyclohexan-1,2-diol.

Besides their acceptor substrate specificity, FucTs have been classified according to their sensitivity toward NEM, which is known to modify proteins by forming a covalent linkage with the sulfhydryl group of cysteine residues (Chou *et al.*, 1977; Campbell and Stanley, 1984). Our bacterial  $\alpha$ -1,4 FucT was inhibited to 90% with 10 mM NEM, whereas the activity of the *H. pylori*  $\alpha$ -1,3 FucT was reduced by only 35% in the presence of 15 mM NEM (Martin *et al.*, 1997). This is in accordance with the data obtained for the corresponding human FucTs (Holmes *et al.*, 1995). Examination of the cysteine distribution within the two highly homologous *H. pylori* enzymes (87% identity) shows two conserved cysteines (Cys164 and Cys233 in  $\alpha$ -1,4 FucT and Cys168 and Cys237 in  $\alpha$ -1,3 FucT) as well as a third cysteine, which is located differently in the two sequences ( $\alpha$ -1,4 FucT: Cys343;  $\alpha$ -1,3 FucT: Cys282). Site-directed mutagenesis analysis should provide the information on the cysteine residue responsible for sensitivity toward NEM.

Finally, it has been shown that differences in *N*-glycosylation affect the thermal stability of FucTs. Therefore, depending on the expression system, FucTs show different thermal profiles, for example *Sf9* versus Namalwa KJM-1 cells (Shinkai *et al.*, 1997). Interestingly, the catalytic activity



of *H. pylori*  $\alpha$ -1,4 FucT expressed in *E. coli* is only slightly affected by elevated temperatures.

In summary, this study reports the complete gene sequence of a novel  $\alpha$ -1,4 FucT. Sequence comparison indicates high similarity with other *H. pylori* FucTs and to a lower extent with eukaryotic FucTs. The enzyme catalyzes almost exclusively the fucosylation of Type I acceptor substrate and mimetics thereof. Whereas active mammalian FucTs cannot be expressed in *E. coli* because of the lack of glycosylation (Kukowska-Latallo *et al.*, 1990; Larsen *et al.*, 1990), the expression of active *H. pylori*  $\alpha$ -1,4 FucT is possible. This allows the cost-effective bacterial production of FucTs in preparative amounts and their use in large-scale enzymatic syntheses of oligosaccharides.

## Materials and methods

### Materials

The *H. pylori* strain was isolated from endoscopic biopsies at the University Hospital, Gävle, Sweden and deposited by Hoffmann-La Roche, Basel, Switzerland, under the number DMS6709 at the Deutsche Sammlung von Mikroorganismen, Braunschweig, Germany. *Escherichia coli* JM109, DH $\alpha$ 5, Top10, and AD494 strains have been purchased from Novagen (Lucerne, Switzerland). Ampicillin, kanamycin and protein standard bovine serum albumin (BSA) were obtained from Sigma (Buchs SG, Switzerland). IgG sepharose column material and GDP-L-[ $^{14}$ C]fucose (287 mCi/mmol) were purchased from Amersham Biosciences (Otelfingen, Switzerland). GDP-hexanolamine was synthesized as described (Bamford *et al.*, 1996) and was coupled to cyanogen bromide-activated sepharose 4B. Type I and Type II acceptor substrates and analogs thereof have been chemically synthesized as described (Hindsgaul *et al.*, 1991; Ernst and Oehrlein, 1999; Ernst *et al.*, 2000b).

### Cloning and expression of *H. pylori* $\alpha$ -1,4 fucosyltransferase

*Helicobacter pylori* genomic DNA was prepared using the genomic DNA extraction kit from Wizard (Promega, Wallisellen, Switzerland). The  $\alpha$ -1,4 FucT gene was amplified by PCR with the high fidelity *pfu* polymerase (Stratagene, Amsterdam, The Netherlands). The forward and reverse primers were designed on the basis of the published *H. pylori*  $\alpha$ -1,3 and  $\alpha$ -1,3/4 FucT sequences (Accession numbers: AF194963, AAD06573, and AAD06169). 5'-EcoRI forward primer (5'-gcgaattcgatgttcagcccttagacgctt-3') and 5'-BamHI reverse primer (5'-gccggatccctattaggaaagtagcgtctgcgat-3') were synthesized at Microsynth (Balgach, Switzerland). The PCR-generated fragment (1375 bp) was treated with EcoRI and BamHI and ligated (T4 DNA-ligase, Promega) into the appropriate site of pEZZ18 cloning vector (Pharmacia-Biotech, Otelfingen, Switzerland). Chemocompetent *E. coli* JM109 cells were transformed with the ligation product, plated on selective Luria-Betani-agar plates and incubated overnight at 37°C. Single colonies were then inoculated in 2 mL LB-medium supplemented with 70  $\mu$ g/mL ampicillin. Plasmid DNA was isolated by miniprep according to the instructions of the supplier (GFX<sup>TM</sup> Micro Plasmid Prep Kit, Amersham Biosciences). The constructs containing two

ZZ domains of protein A and the coding sequence for *H. pylori* FucT were verified by PCR and restriction enzyme digestion. DNA sequence analysis was performed by double-stranded sequence reactions by Microsynth. The recombinant vector was then transformed into the *E. coli* strains DH $\alpha$ 5, Top10, and AD494.

### Bacterial culture and protein production

The bacterial clones containing the pEZZ18/FucT construct were grown overnight with vigorous shaking (300 rpm) at 37°C and in 50 mL Terrific Broth medium (TB, Becton Dickinson, Basel, Switzerland) containing ampicillin (70  $\mu$ g/mL) and additionally kanamycin (25  $\mu$ g/mL) for AD494 cells. After 16 h the cells were collected by centrifugation for 20 min at 5000 rpm and 4°C. Aliquots (5 mL) from supernatants and cell lysates were concentrated by ultrafiltration to 50  $\mu$ L volume (Amicon YM 50) and tested for enzyme activity.

### Purification of *H. pylori* $\alpha$ -1,4 fucosyltransferase

The supernatant of the overnight bacterial culture was collected by centrifugation and filtration (0.2  $\mu$ m, Millipore, Volketswil, Switzerland). The filtrate was adjusted to pH 7.6 with 2.5 M Tris-HCl solution. After loading the supernatant on the IgG-sepharose-6 column (Pharmacia-Biotech) attached to the BioLogic fast protein liquid chromatography system (BioRad, Reinach BL, Switzerland) two washing steps were performed, the first with 10 bed volumes of buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, and 0.05% Tween 20 and the second with 2 bed volumes of 5 mM NH<sub>4</sub>OAc (pH 5.0). The enzyme was eluted with 10 mL of 500 mM NH<sub>4</sub>OAc (pH 3.4). The collected fractions were immediately neutralized with 2.5 M Tris-HCl solution and concentrated by ultrafiltration (Amicon, YM 50) to a volume of 50  $\mu$ L. In a second ultrafiltration step, the buffer was exchanged by cacodylate buffer (pH 6.5).

In a second purification strategy, the supernatant of a bacterial overnight culture was conditioned with 20 mM MnCl<sub>2</sub> and loaded on a GDP-hexanolamine column according to the procedure described (De Vries *et al.*, 2001). The protein concentration of pooled active fractions was determined by the Bradford assay using bovine serum albumin (BSA, Sigma) as a standard.

### SDS-PAGE analysis

Protein electrophoresis was performed on 10% polyacrylamide gel according to the method of Laemmli (1970). The purity of eluted fractions was verified by silver-staining (Silver staining Kit, Pharmacia-Biotech) using low molecular weight marker (Sigma).

### Fucosyltransferase assay

The reactions, run in duplicates, were conducted in a total volume of 30  $\mu$ L containing 50 mM cacodylate (pH 6.5), 20 mM MnCl<sub>2</sub>, 0.150 mM GDP-fucose, 55,000 cpm GDP-[ $^{14}$ C]fucose (287 mCi/mmol, Amersham Pharmacia), 3  $\mu$ g BSA (Sigma), 0.01 mM acceptor substrate, and 15 mU of *H. pylori*  $\alpha$ -1,4 FucT. After 30 min of incubation at 37°C,

the reaction was stopped by the addition of 1 mL of water and loaded onto a Sep-Pak-C<sub>18</sub> cartridge (Waters, Ruppertswil, Switzerland). The cartridge was washed twice with 5 mL bidistilled water and eluted with 5 mL methanol. The transfer rate of [<sup>14</sup>C]Fuc onto the acceptor substrate was determined by liquid scintillation counting. The activity of the enzyme was calculated as a percentage of radioactivity counted in the methanol fraction.

#### Determination of kinetic parameters

The kinetic parameters were determined using 0.150 mM of GDP-fucose and concentrations of the acceptor substrates ranging from 0.05 to 2 mM. For the determination of the  $K_m$  for GDP-fucose, the concentration of the Type I acceptor substrate **1** was kept at 2 mM. Reaction mixtures were prepared as described above.

#### Thermal stability of the recombinant *H. pylori* $\alpha$ -1,4 fucosyltransferase

The temperature stability of the enzyme was measured in cacodylate buffer at pH 6.5 by preincubating the enzyme at different temperatures ranging from 25 to 55°C for 5 min. The reaction mixtures were then incubated for further 30 min at the indicated temperatures. The activity of the enzyme was quantified as described above.

#### Treatment with NEM

To verify the susceptibility of the novel *H. pylori*  $\alpha$ -1,4 FucT to the sulfhydryl-binding reagent, various amounts of NEM were added to the assay reaction to give final concentrations of 0.5–10 mM. The reaction was cooled for 30 min on ice before incubation with **1** and quantified as described above.

#### Acknowledgments

Financial support was generously provided by the Swiss National Science Foundation. In addition, we thank YAMASA Corp., Tokyo, Japan for the generous gift of GDP-fucose.

#### Abbreviations

BSA, bovine serum albumin; FucT, fucosyltransferase; Gal, galactose; GDP-fucose, guanine 5'-diphospho- $\beta$ -L-fucose; LacNAc, *N*-acetylactosamine; Le<sup>a</sup>, Lewis A, Gal $\beta$ -1,3(Fuc $\alpha$ -1,4)GlcNAc; Lem, Lemieux spacer, (CH<sub>2</sub>)<sub>8</sub>COOMe; NEM, *N*-ethylmaleimide; NeuNAc, *N*-acetylneuraminic acid; sLe<sup>a</sup>, sialyl Lewis A, NeuNAc $\alpha$ -2,3Gal $\beta$ -1,3(Fuc $\alpha$ -1,4)GlcNAc; PCR, polymerase chain reaction; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; Type I, Gal $\beta$ -1,3GlcNAc; Type II, Gal $\beta$ -1,4GlcNAc.

#### References

Alm, R.A., Ling, S.L., Moir, D.T., King, B.L., Brown, E.D., Doig, P.C., Smith, D.R., Noonan, B., Guild, B.C., de Jonge, B.L., and others. (1999) Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen *Helicobacter pylori*. *Nature*, **397**, 176–180.

Appelmek, B.J., Simoons-Smit, I., Negrini, R., Moran, A.P., Aspinall, G.O., Forte, J.G., De Vries, T., Quan, H., Verboom, T., Maaskant, J.J., and others. (1996) Potential role of molecular mimicry between *Helicobacter pylori* lipopolysaccharide and host Lewis blood group antigens in autoimmunity. *Infect. Immun.*, **64**, 2031–2040.

Baisch, G., Öhrlein, R., and Ernst, B. (1996a) Enzymatic galactosylation of non-natural glucosamide-acceptors. *Bioorg. Med. Chem. Lett.*, **6**, 749–754.

Baisch, G., Öhrlein, R., Katopodis, A., and Ernst, B. (1996b) Enzymatic fucosylation of non-natural trisaccharides with cloned fucosyltransferase VI. *Bioorg. Med. Chem. Lett.*, **6**, 759–762.

Baisch, G., Öhrlein, R., Streiff, M., and Ernst, B. (1996c) Enzymatic  $\alpha$ -(2,3)-sialylation of non-natural disaccharides with cloned sialyltransferase. *Bioorg. Med. Chem. Lett.*, **6**, 755–758.

Bamford, M., Britte, Ch., Draeger, E., Gore, P., and Holmes, D.S. (1996) An improved method for the synthesis of GDP-hexanolamine derivatives, key reagents for the purification and characterization of carbohydrate processing enzymes. *J. Carbohydr. Chem.*, **15**, 727–737.

Bintein, F., Auge, C., and Lubineau, A. (2003) Chemo-enzymatic synthesis of a divalent sialyl Lewis (x) ligand with restricted flexibility. *Carbohydr. Res.*, **338**, 1163–1173.

Blixt, O., Allin, K., Pereira, L., Datta, A., and Paulson, J.C. (2002) Efficient chemoenzymatic synthesis of *O*-linked sialyl oligosaccharides. *J. Am. Chem. Soc.*, **124**, 5739–5746.

Campbell, C. and Stanley, P. (1984) The Chinese hamster ovary glycosylation mutants LEC11 and LEC12 express two novel GDP-fucose: *N*-acetylglucosaminide-3- $\alpha$ -L-fucosyltransferase enzymes. *J. Biol. Chem.*, **259**, 11208–11214.

Chan, N.W., Stangier, K., Sherburne, R., Taylor, D.E., Zhang, Y., Dovichi, N.J., and Palcic, M.M. (1995) The biosynthesis of Lewis<sup>x</sup> in *Helicobacter pylori*. *Glycobiology*, **5**, 683–688.

Chou, H.T., Murphy, C., and Kessel, D. (1977) Selective inhibition of a plasma fucosyltransferase by *N*-ethylmaleimide. *Biochem. Biophys. Res. Commun.*, **74**, 1001–1006.

Costache, M., Apoil, P.A., Cailleau, A., Elmgren, A., Larson, G., Henry, S., Blancher, A., Iordachescu, D., Oriol, R., and Mollicone, R. (1997) Evolution of fucosyltransferase genes in vertebrates. *J. Biol. Chem.*, **272**, 29721–29728.

De Vries, T., Storm, J., Rottevel, F., Verdonk, G., van Duin, M., van den Eijnden, D.H., Joziassé, D.H., and Bunschoten, H. (2001) Production of soluble human  $\alpha$ 3-fucosyltransferase (FucT VII) by membrane targeting and in vivo proteolysis. *Glycobiology*, **11**, 711–717.

Derman, A.I., Prinz, W.A., Belin, D., and Beckwith, J. (1993) Mutations that allow disulfide bond formation in the cytoplasm of *Escherichia coli*. *Science*, **262**, 1744–1747.

Ernst, B. and Öhrlein, R. (1999) Substrate and donor specificity of glycosyl transferases. *Glycoconj. J.*, **16**, 161–170.

Ernst, B., Hart, G.W., and Sinaý, P. (eds) (2000a) *Carbohydrates in Chemistry and Biology, Chemical Synthesis of Glycosides and Glycomimetics*. Wiley-VCH, Weinheim, Germany, Vol. 1.

Ernst, B., Wagner, B., Baisch, G., Katopodis, A., Winkler, T., and Öhrlein, R. (2000b) Substrate specificity of fucosyltransferase III: an efficient synthesis of sialyl Lewis<sup>x</sup>, Lewis<sup>a</sup>-derivatives and mimetics thereof. *Can. J. Chem.*, **78**, 892–903.

Ge, Z., Chan, N.W., Palcic, M.M., and Taylor, D.E. (1997) Cloning and heterologous expression of an  $\alpha$ 1,3-fucosyltransferase gene from the gastric pathogen *Helicobacter pylori*. *J. Biol. Chem.*, **272**, 21357–21363.

Gijzen, H.J.M., Qiao, L., Fitz, W., and Wong, C.-H. (1996) Recent advances in the chemoenzymatic synthesis of carbohydrates and carbohydrate mimetics. *Chem. Rev.*, **96**, 443–473.

Gilbert, M., Watson, D.C., Cunningham, A.M., Jennings, M.P., Young, N.M., and Wakarchuk, W.W. (1996) Cloning of the lipooligosaccharide  $\alpha$ -2,3-sialyltransferase from the bacterial pathogens *Neisseria meningitidis* and *Neisseria gonorrhoeae*. *J. Biol. Chem.*, **271**, 28271–28276.

Gilbert, M., Brisson, J.R., Karwaski, M.F., Michniewicz, J., Cunningham, A.M., Wu, Y., Young, N.M., and Wakarchuk, W.W. (2000) Biosynthesis of ganglioside mimics in *Campylobacter jejuni* OH4384. Identification of the glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-MHz <sup>1</sup>H and <sup>13</sup>C NMR analysis. *J. Biol. Chem.*, **275**, 3896–3906.

Hindsgaul, O., Kaur, K.J., Srivastava, G., Blaszczyk-Thurin, M., Crawley, S.C., Heerze, L.D., and Palcic, M.M. (1991) Evaluation of deoxygenated

- oligosaccharide acceptor analogs as specific inhibitors of glycosyltransferases. *J. Biol. Chem.*, **266**, 17858–17862.
- Holmes, E.H., Xu, Z., Sherwood, A.L., and Macher, B.A. (1995) Structure-function analysis of human  $\alpha$ (1,3) fucosyltransferases. *J. Biol. Chem.*, **270**, 8145–8151.
- Kim, H.G., Yang, S.M., Lee, Y.C., Do, S.I., Chung, I.S., and Yang, J.M. (2003) High-level expression of human glycosyltransferases in insect cells as biochemically active form. *Biochem. Biophys. Res. Commun.*, **305**, 488–493.
- Kitagawa, H. and Paulson, J.C. (1994) Cloning of a novel alpha 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups. *J. Biol. Chem.*, **269**, 1394–1401.
- Kukowska-Latallo, J.F., Larsen, R.D., Nair, R.P., and Lowe, J.B. (1990) A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha (1,3/1,4) fucosyltransferase. *Genes Dev.*, **4**, 1288–1303.
- Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **227**, 680–685.
- Landschulz, W.H., Johnson, P.F., and McKnight, S.L. (1988) The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. *Science*, **240**, 1759–1764.
- Larsen, R.D., Ernst, L.K., Nair, R.P., and Lowe, J.B. (1990) Molecular cloning, sequence, and expression of a human GDP-L-fucose: beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can form the H blood group antigen. *Proc. Natl. Acad. Sci. U. S. A.*, **87**, 6674–6678.
- Ma, B., Wang, G., Palcic, M.M., Hazes, B., and Taylor, D.E. (2003) C-terminal amino acids of *Helicobacter pylori*  $\alpha$ (1,3/4)fucosyltransferases determine Type I and Type II transfer. *J. Biol. Chem.*, **278**, 21893–21900.
- Malissard, M., Zeng, S., and Berger, E.G. (2000) Expression of functional soluble forms of human beta 1,4-galactosyltransferase I, alpha 2,6-sialyltransferase, and alpha 1,3-fucosyltransferase VI in the methylotrophic yeast *Pichia pastoris*. *Biochem. Biophys. Res. Commun.*, **267**, 169–173.
- Martin, S.L., Edbrooke, M.R., Hodgman, T.C., van den Eijnden, D.H., and Bird, M.I. (1997) Lewis<sup>x</sup> biosynthesis in *Helicobacter pylori*. Molecular cloning of an  $\alpha$ (1,3)-fucosyltransferase gene. *J. Biol. Chem.*, **272**, 21349–21356.
- Monteiro, M.A., Chan, K.H., Rasko, D.A., Taylor, D.E., Zheng, P.Y., Appelmelk, B.J., Wirth, H.-P., Yang, M., Blaser, M.J., Hynes, S.O., and others. (1998) Simultaneous expression of Type I and Type II Lewis blood group antigens by *Helicobacter pylori* lipopolysaccharides. Molecular mimicry between *H. pylori* lipopolysaccharides and human gastric epithelial cell surface glycoforms. *J. Biol. Chem.*, **273**, 11533–11543.
- Morais, V.A., Serpa, J., Palma, A.S., Costa, T., Maranga, L., and Costa, J. (2001) Expression and characterization of recombinant human alpha-3/4-fucosyltransferase III from *Spodoptera frugiperda* (Sf9) and *Trichoplusia ni* (Tn) cells using the baculovirus expression system. *Biochem. J.*, **353**, 719–725.
- Oulmouden, A., Wierinckx, A., Petit, J.M., Costache, M., Palcic, M.M., Mollicone, R., Oriol, R., and Julien, R. (1997) Molecular cloning and expression of a bovine  $\alpha$ (1,3)fucosyltransferase gene homologous to a putative ancestor gene of the human *FUT3-FUT5-FUT6* cluster. *J. Biol. Chem.*, **272**, 8764–8773.
- Palcic, M.M. and Hindsgaul, O. (1991) Flexibility in the donor substrate specificity of beta 1,4-galactosyltransferase: application in the synthesis of complex carbohydrates. *Glycobiology*, **1**, 205–209.
- Rasko, D.A., Wang, G., Palcic, M.M., and Taylor, D.E. (2000) Cloning and characterization of the  $\alpha$ (1,3/4) fucosyltransferase of *Helicobacter pylori*. *J. Biol. Chem.*, **275**, 4988–4994.
- Seto, N.O., Compston, C.A., Szpacenko, A., and Palcic, M.M. (2000) Enzymatic synthesis of blood group A and B trisaccharide analogues. *Carbohydr. Res.*, **324**, 161–169.
- Shinkai, A., Shinoda, K., Sasaki, K., Morishita, Y., Nishi, T., Matsuda, Y., Takahashi, I., and Anazawa, H. (1997) High-level expression and purification of a recombinant human alpha-1,3fucosyltransferase in baculovirus-infected insect cells. *Protein. Expr. Purif.*, **10**, 379–385.
- Simoons-Smit, I.M., Appelmelk, B.J., Verboom, T., Negrini, R., Penner, J.L., and Aspinall, G.O. (1996) Typing of *Helicobacter pylori* with monoclonal antibodies against Lewis antigens in lipopolysaccharide. *J. Clin. Microbiol.*, **34**, 2196–2200.
- Tomb, J.F., White, O., Kerlavage, A.R., Clayton, R.A., Sutton, G.G., Fleischmann, R.D., Ketchum, K.A., Klenk, H.P., Gill, S., Dougherty, B.A., and others. (1997) The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature*, **388**, 539–547.
- Wang, G., Boulton, P.G., Chan, N.W., Palcic, M.M., and Taylor, D.E. (1999) Novel *Helicobacter pylori* alpha-1,2 fucosyltransferase, a key enzyme in the synthesis of Lewis antigens. *Microbiology*, **145**, 3245–3253.
- Wang, G., Ge, Z., Rasko, D.A., and Taylor, D.E. (2000) Lewis antigens in *Helicobacter pylori*: biosynthesis and phase variation. *Mol. Microbiol.*, **36**, 1187–1196.
- Weston, B.W., Nair, R.P., Larsen, R.D., and Lowe, J.B. (1992) Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4)fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities. *J. Biol. Chem.*, **267**, 4152–4160.
- Wirth, H.P., Yang, M., Karita, M., and Blaser, M.J. (1996) Expression of the human cell surface glycoconjugates Lewis<sup>x</sup> and Lewis<sup>y</sup> by *Helicobacter pylori* isolates is related to cagA status. *Infect. Immun.*, **64**, 4598–4605.
- Xu, Z., Vo, L., and Macher, B.A. (1996) Structure-function analysis of human  $\alpha$ 1,3-fucosyltransferase. *J. Biol. Chem.*, **271**, 8818–8823.